KLLJ Investments
Contributor since: 2010
Latest Articles
Arena Pharmaceuticals - A Biotech Value Investment
Arena Pharmaceuticals - Why I Believe It Is The Next Major Biotech
Arena: The Improving Odds Of A Belviq Blockbuster
Arena: The Belviq Launch And Why The Short Thesis Is Wrong
Arena's Recent Outperform Call And A Probability Weighted Valuation
Arena Breaking Out Ahead Of European Approval
The Approaching Arena Battle
Assessing Arena's Belviq As A Diabesity Drug
Important Insights For Arena Pharmaceuticals
Are Qsymia's Launch Challenges A Category Problem?
The Vivus Exit Continues
Is Arena The Next Alexion?
A Valuation Model For Arena's Belviq
Why Analysts Still Have It Wrong With Arena
Is Arena Still A Speculative Stock?
Preview Of Arena's Upcoming Advisory Committee
Arena Pharmaceuticals' Lorcaserin Will Be A Blockbuster Drug
Weight Loss Drugs: Why Arena's Is Likely To Win Approval Before Vivus's
Is Arena's Lorcaserin On Track For Approval In 2012?
VirnetX Is on Fire: Join the Party Before It's Too Late
Sangamo BioSciences' Platform Could Be the Future of Biotech
MannKind's Path Forward
MannKind’s Afrezza Has Mega-Blockbuster Potential
Clearing Up the Uncertainty Around MannKind's Afrezza
Afrezza’s Market Potential and the Future Value of MannKind
Lorcaserin’s Path to Approval
What Analysts Won't Tell You About Arena
Is Lorcaserin the New Miracle Drug?
Is Mannkind the Next Takeover Target?
Arena Inks a Potential Blockbuster Deal
MannKind Bear Analysts Strike Again
A Giant Leap for MannKind